

## Product Information

### Anti-Muscarinic Acetylcholine Receptor (M<sub>2</sub>)

produced in rabbit, affinity isolated antibody

Catalog Number **M9558**

#### Product Description

Anti-Muscarinic Acetylcholine Receptor (M<sub>2</sub>) is produced in rabbit using as immunogen a highly purified GST fusion protein of a part of the i3 intracellular loop of human M<sub>2</sub> muscarinic acetylcholine receptor (mAChR) corresponding to amino acid residues 227-356<sup>1,2</sup>. The antibody is affinity isolated using GST fusion protein-agarose.

Anti-Muscarinic Acetylcholine Receptor (M<sub>2</sub>) recognizes human, mouse and rat M<sub>2</sub> muscarinic acetylcholine receptor by immunoblotting. The antibody may also be used for immunohistochemistry,<sup>3</sup> and immunoprecipitation.<sup>3,4</sup>

Acetylcholine actions are mediated by two classes of receptor, nicotinic or muscarinic receptors. Five subtypes (M<sub>1</sub>-M<sub>5</sub>) of muscarinic receptors have been identified.<sup>5</sup> Muscarinic receptors are members of the G protein-coupled receptor family. M<sub>1</sub>, M<sub>3</sub> and M<sub>5</sub> activate phospholipases A<sub>2</sub>, C or D, or tyrosine kinase and M<sub>2</sub> and M<sub>4</sub> attenuate adenylate cyclase or augment phospholipase A<sub>2</sub>.<sup>5</sup> Muscarinic receptors are expressed throughout the CNS with M<sub>2</sub> receptors enriched in the cerebellum, pons/medulla and thalamus/hypothalamus whereas M<sub>1</sub> receptors are enriched in hippocampus, striatum and olfactory tubule.<sup>6,7</sup> Peripherally, M<sub>2</sub> receptors represent over 90% of the muscarinic receptors in heart<sup>6</sup> and both m<sub>1</sub> and m<sub>2</sub> are expressed in airways.<sup>8</sup>

Muscarinic receptors have various presynaptic and postsynaptic effects that are important in both information processing and plastic changes in CNS function. One major role of M<sub>2</sub> receptors is as autoreceptors and heteroreceptors to control neurotransmitter release.<sup>9</sup> Muscarinic receptors may be important in changes associated with learning and memory. Evidence implicates M<sub>1</sub> receptors in mossy fiber LTP<sup>10</sup> and M<sub>2</sub> receptors mediate muscarinic LTP.<sup>11</sup> Another functional area where both M<sub>1</sub> and M<sub>2</sub> are implicated, but probably play different roles, is in cholinergic modulation of visual input.<sup>12</sup>

Alterations in muscarinic receptors or function have been implicated in some neurological disorders including Down's Syndrome, Alzheimer's and Parkinson's disease.<sup>5</sup> M<sub>1</sub> receptors may contribute to the development of ischemic brain damage.<sup>13</sup> Interestingly, alterations in both M<sub>1</sub> and M<sub>2</sub> receptors may be implicated in different forms of cortical dementia with M<sub>1</sub> implicated in DLBD (diffuse Lewy body disease) and M<sub>2</sub> in Alzheimer's.<sup>14</sup>

Peripherally, alterations in M<sub>2</sub> function may be implicated in viral lung infections<sup>15</sup> and asthma.<sup>16</sup> The presence of anti-M<sub>2</sub>-muscarinic receptor autoantibodies may lead to alterations in M<sub>2</sub> function and thus to heart dysfunction.<sup>17,18</sup>

Although much has been learned about the structure and function of these muscarinic receptors, much remains to be determined about their precise cellular localization and *in vivo* physiological roles, their possible roles in disease states and their roles in mediating therapeutic drug effects.

#### Reagent

Supplied as a lyophilized powder from phosphate buffered saline, pH 7.4, containing 1% bovine serum albumin, and 0.05% sodium azide.

#### Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

#### Preparation Instructions

Reconstitute the lyophilized vial with 0.05 or 0.2 mL deionized water, depending on the package size purchased. Antibody dilutions should be made in buffer containing 1-3% bovine serum albumin.

### Storage/Stability

Prior to reconstitution, store at  $-20^{\circ}\text{C}$ . After reconstitution, the stock antibody solution may be stored at  $2-8^{\circ}\text{C}$ . for up to two weeks. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

### Product Profile

**Immunoblotting:** the recommended working dilution is 1:200 (1.5  $\mu\text{g}/\text{mL}$ ) using rat brain membranes, Anti-Rabbit IgG-Peroxidase conjugate and detection by ECL.

**Note:** In order to obtain best results and assay sensitivities of different techniques and preparations, we recommend determining optimal working dilutions by titration test.

### References

1. Bonner, T.I., et al., *Science*, **237**, 527 (1987).
2. Peralta, E.G., et al., *EMBO J.*, **6**, 3923 (1987).
3. Levey, A.I., et al., *J. Neurosci.*, **11**, 3218 (1991).
4. Levey, A.I., et al., *FEBS Lett.*, **275**, 65 (1990).
5. Felder, C.C., *FASEB J.*, **9**, 619 (1995).
6. Li, M. et al., *Mol. Pharm.*, **40**, 28 (1991).
7. Wall, S.J. et al., *Mol. Pharm.*, **39**, 643 (1991).
8. Barnes, P.J., *Agents Actions Suppl.*, **43**, 243 (1993).
9. Levey, A.I. et al., *J. Neurosci.*, **15**, 4077 (1995).
10. Kaneko, S. et al., *Behav. Brain Res.*, **83**, 45 (1997).
11. Segal, M. and Auerbach, J.M., *Life Sci.*, **60**, 1085 (1997).
12. Tigges, M. et al., *J. Comp. Neurol.*, **388**, 130 (1997).
13. Jiang, Z.W. et al., *Brain Res.*, **852**, 37 (2000).
14. Shiozaki, K. et al., *J. Neurol. Neurosurg. Psychiatry*, **67**, 209 (1999).
15. Jacoby, D.B. and Fryer, A.D., *Clin. Exp. Allergy*, **29**, 59 (1999).
16. Fryer, A.D. et al., *Life Sci.*, **64**, 449 (1999).
17. Retondaro, F.C. et al., *FASEB J.*, **13**, 2015 (1999).
18. Matsui, S. et al., *J. Card. Fail.*, **5**, 246 (1999).

JJJ,PHC 05/12-1